Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2024 | Promising targets in headache research: PACAP

Alan Rapoport, MD, University of California, Los Angeles, CA, discusses the therapeutic potential of pituitary adenylate cyclase activating polypeptide (PACAP) as a target in headache management. PACAP is a neuropeptide implicated in a wide range of functions, including nociception. Studies indicate that systemic PACAP infusion triggers migraine-like attacks in patients with migraine and increased plasma levels have been recorded in migraine and cluster headache attacks. Initially, attempts to block PACAP using antibodies to its receptor failed. However, a recent study using antibodies directly to PACAP shows promise. If further studies prove successful, PACAP blockade could be a ground-breaking migraine treatment. Dr Rapoport, reflecting on his 56 years in neurology, notes the remarkable evolution of migraine therapies from one drug to numerous options today, expressing optimism for future advancements within 3 to 10 years. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.